To explore candidate repurposable drugs as a therapy for SARS-CoV-2 infections with one or more lung diseases, we choose our suggested 11 hub-sDEGs based proteins (STAT1, TLR4, CXCL10, CCL2, JUN, DDX58, IRF7, ICAM1, MX2, IRF9, and ISG15) and its regulatory 6 key TFs proteins (MYC, SOX2, CEBPA, NANOG, RELA, and MSX1) as the m = 17 target proteins and 184 meta-drug agents (ligands). This evidence concerns the gene IRF9 and lung disorder.